Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5+Ida), and 5 days + Cladribine (SGI5+Clad), in Previously Untreated Patients = 70 Years with Acute Myeloid Leukemia (AML)-a Bayesian Design

Naqvi Kiran; Gonzalez Garciela Nogueras; Cheung Cora; Pemmaraju Naveen; Jabbour Elias; Garcia-Manero Guillermo; DiNardo Courtney; Ohanian Maro; Jain Nitin; Takahashi Koichi; Alvarado Yesid; Konopleva Marina; Huang Xuelin; Cortes Jorge; Kantarjian Hagop

首页> 外文期刊>Clinical lymphoma, myeloma & leukemia >Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5+Ida), and 5 days + Cladribine (SGI5+Clad), in Previously Untreated Patients = 70 Years with Acute Myeloid Leukemia (AML)-a Bayesian Design

【24h】

Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5+Ida), and 5 days + Cladribine (SGI5+Clad), in Previously Untreated Patients = 70 Years with Acute Myeloid Leukemia (AML)-a Bayesian Design

机译：基于瓜鹃（SGI-110）的随机阶段II研究比较瓜鹃阿硝滨5天（SGI5），10天（SGI10），5天+偶霉素（SGI5 + IDA）和5天+ Cladribine（SGI5 + Clad），在前一种方案未经治疗的患者＆ = 70年急性髓性白血病（AML）-A贝叶斯设计

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical lymphoma, myeloma & leukemia》 |2017年第10suppla期|共1页
作者
Naqvi Kiran; Gonzalez Garciela Nogueras; Cheung Cora; Pemmaraju Naveen; Jabbour Elias; Garcia-Manero Guillermo; DiNardo Courtney; Ohanian Maro; Jain Nitin; Takahashi Koichi; Alvarado Yesid; Konopleva Marina; Huang Xuelin; Cortes Jorge; Kantarjian Hagop;
展开▼
作者单位

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5+Ida), and 5 days + Cladribine (SGI5+Clad), in Previously Untreated Patients = 70 Years with Acute Myeloid Leukemia (AML)-a Bayesian Design [J] . Naqvi Kiran, Gonzalez Garciela Nogueras, Cheung Cora, Clinical lymphoma, myeloma & leukemia . 2017,第10Suppla期

机译：基于瓜鹃（SGI-110）的随机阶段II研究比较瓜鹃阿硝滨5天（SGI5），10天（SGI10），5天+偶霉素（SGI5 + IDA）和5天+ Cladribine（SGI5 + Clad），在前一种方案未经治疗的患者＆ = 70年急性髓性白血病（AML）-A贝叶斯设计
2. Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia(r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies [J] . Daver Naval, Kantarjian Hagop M., Roboz Gail J., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：在第2期研究中，接受瓜德西他滨（SGI-110）治疗的103位复发/难治性急性髓性白血病（r / r AML）患者的各种预后亚组的长期生存和临床完全缓解
3. Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia(r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies [J] . Daver Naval, Kantarjian Hagop M., Roboz Gail J., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：在第2期研究中，接受瓜德西他滨（SGI-110）治疗的103位复发/难治性急性髓性白血病（r / r AML）患者的各种预后亚组的长期生存和临床完全缓解
4. Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective Multicenter Study in Korea [O] . Dae Hyoung Lee, Nak Gyun Chung, Bin Cho, 2010

机译：Idarubicin加山hen酰基阿糖胞苷和6-硫代鸟嘌呤与Idarubicin加阿糖胞苷的治疗方案对先前未经治疗的急性髓样白血病的儿童具有良好的对比：在韩国进行的10年回顾性多中心研究
5. Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea [O] . Lee, Dae Hyoung, Chung, Nak Gyun, Cho, Bin, 2010

机译：Idarubicin加山hen酰基阿糖胞苷和6-硫代鸟嘌呤与Idarubicin加阿糖胞苷的治疗方案对以前未经治疗的急性髓样白血病的儿童具有良好的对比：在韩国进行的10年回顾性多中心研究

Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5+Ida), and 5 days + Cladribine (SGI5+Clad), in Previously Untreated Patients = 70 Years with Acute Myeloid Leukemia (AML)-a Bayesian Design

著录项

相似文献

相关主题

期刊订阅